CLYYF News and Press, Celyad SA From 12/22/20

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

Celyad Oncology SA (CYAD) First Half 2020 Earnings Conference Call August 07, 2020 8:00 AM ET Company Participants Filippo Petti – Chief Executive Officer David Gilham – Chief Scientific Officer Conference Call Participants Raju Prasad – William Blair J...

Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...

Celyad Reports Positive Update on Non Gene Edited Allogeneic CAR-T Therapy Celyad ( CYAD ) announced update for its Phase 1 clinical trial alloSHRINK. The trial aims to assess the potential of its lead drug candidate CYAD-101 for patients suffering from metastatic colorectal cancer. It e...

Celyad SA (CYAD) Q4 2019 Earnings Conference Call March 25, 2020 08:00 a.m. ET Company Representatives Filippo Petti - Chief Executive Officer David Gilham - Vice President of Research & Development Frédéric Lehmann - Vice President of Global Clinical Development an...

Introduction Celyad ( CYAD ) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizo...